Legacy Financial Advisors Inc. Purchases 995 Shares of Bristol-Myers Squibb (NYSE:BMY)

Legacy Financial Advisors Inc. grew its holdings in Bristol-Myers Squibb (NYSE:BMY) by 27.1% during the 1st quarter, Holdings Channel reports. The fund owned 4,666 shares of the biopharmaceutical company’s stock after buying an additional 995 shares during the period. Legacy Financial Advisors Inc.’s holdings in Bristol-Myers Squibb were worth $295,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in BMY. OLD Mission Capital LLC bought a new position in shares of Bristol-Myers Squibb during the third quarter worth $234,000. Brinker Capital Investments LLC acquired a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $3,777,000. Thomasville National Bank raised its holdings in shares of Bristol-Myers Squibb by 1.8% during the fourth quarter. Thomasville National Bank now owns 80,077 shares of the biopharmaceutical company’s stock valued at $4,967,000 after acquiring an additional 1,446 shares during the last quarter. Kempner Capital Management Inc. raised its stake in Bristol-Myers Squibb by 40.5% during the fourth quarter. Kempner Capital Management Inc. now owns 48,900 shares of the biopharmaceutical company’s stock worth $3,033,000 after purchasing an additional 14,095 shares during the period. Finally, Private Asset Management Inc. raised its holdings in Bristol-Myers Squibb by 2.3% in the 4th quarter. Private Asset Management Inc. now owns 162,483 shares of the biopharmaceutical company’s stock valued at $10,079,000 after buying an additional 3,727 shares during the period. 72.41% of the stock is owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of the stock in a transaction that occurred on Monday, March 22nd. The stock was sold at an average price of $62.20, for a total transaction of $1,555,000.00. Following the transaction, the chief executive officer now owns 528,980 shares of the company’s stock, valued at approximately $32,902,556. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.14% of the stock is owned by company insiders.

Several brokerages have commented on BMY. Truist Financial raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Tuesday, April 13th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research note on Tuesday, April 6th. Truist Securities upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and upped their price target for the company from $66.00 to $74.00 in a research report on Monday, April 19th. Morgan Stanley cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $70.00 to $62.00 in a research report on Friday. Finally, Truist upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $73.81.

NYSE BMY opened at $63.48 on Tuesday. The company has a 50-day moving average of $63.60 and a 200-day moving average of $63.04. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. Bristol-Myers Squibb has a 12 month low of $54.07 and a 12 month high of $67.16. The company has a market cap of $141.81 billion, a P/E ratio of -577.04, a P/E/G ratio of 1.00 and a beta of 0.67.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.82 by ($0.08). Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The company had revenue of $11.07 billion for the quarter, compared to analysts’ expectations of $11.19 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.35 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Thursday, April 1st were given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date was Wednesday, March 31st. Bristol-Myers Squibb’s payout ratio is currently 41.79%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Featured Story: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.